Correction: The dual PI3K/mTOR inhibitor dactolisib elicits anti-tumor activity in vitro and in vivo.

Correction: The dual PI3K/mTOR inhibitor dactolisib elicits anti-tumor activity in vitro and in vivo.

Oncotarget. 2018 Mar 30;9(24):17255

Authors: Shi F, Zhang J, Liu H, Wu L, Jiang H, Wu Q, Liu T, Lou M, Wu H

Abstract
[This corrects the article DOI: 10.18632/oncotarget.23091.].

PMID: 29683149 [PubMed - in process]

https://ift.tt/2qWlH7I